
The FDA has approved trilaciclib (Cosela) to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.

The FDA has approved trilaciclib (Cosela) to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.

Investigators believe that an effective HIV vaccine would need to produce broadly neutralizing antibodies that would work on different strains of the virus.

Data show that 1 in 5 men and women worldwide develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease, according to the study.

A biologics license application has been submitted to the FDA for the accelerated approval of tisotumab vedotin for use in patients with recurrent or metastatic cervical cancer that has progressed on or following chemotherapy.

Libtayo is the first treatment to show a clinical benefit in patients with advanced basal cell carcinoma after hedgehog pathway inhibitor therapy in a pivotal trial.

Patients with multiple sclerosis who rely on family members as caregivers may be at particular risk for mistreatment, as those caregivers struggle to balance work, childcare, and health concerns of their own.

The findings suggest that the prevalence of these conditions among cancer survivors is nearly 40% higher than that in the general population.

Women whose tumors responded to estrogen treatment were found to benefit from hormone therapy, whereas those whose tumors did not respond experienced worsening disease.

The BTD designations for asciminib were based on the phase 3, multicenter, open-label, randomized ASCEMBL trial and a phase I trial that included patients with Ph+ CML, some of them harboring the T315I mutation.

Of 192 study participants who received Breyanzi, 73% achieved a response, including 54% who had minimal or no detectable lymphoma remaining following treatment and 19% who achieved a partial response.

The FDA has granted an accelerated approval to umbralisib for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.

MET exon 14 skipping alterations occur in approximately 3% of adenocarcinomas and approximately 2% in other lung neoplasms, making them attractive potential targets for lung cancer treatment.

The collaboration begins today, which is also World Cancer Day, and the organizations will be working together to develop and share resources and educational information for the medically integrated oncology pharmacy team.

The findings suggest pre-diagnosis aspirin use might help reduce CRC mortality in the overall population by limiting metastatic spread of colorectal tumors before diagnosis.

Burnout often results from long hours, a highly regulated industry with a lot of change, and just the nature of health care in general.

Pharmacy managers should offer access and incentivize pharmacy staff to take part in self-development activities that can promote self-efficacy.

Patients with AML that has gone into remission following initial chemotherapy were found to remain in remission longer and have improved OS if they took a pill form of azacitidine as a maintenance treatment.

The guidelines recommend discontinuing routine mammograms for survivors with a life expectancy under 5 years, considering stopping screening for those with a 5- to 10-year life expectancy, and continuing mammography for those whose life expectancy is greater than 10 years.

How health system specialty pharmacies can leverage data to differentiate the impact of the high-touch, integrated care model and create value for all pharmacy stakeholders.

In an interview, Nishita Hira, PharmD, CSP, clinical program manager at AllianceRx Walgreens Prime, discussed the role specialty pharmacists can play during the COVID-19 vaccine rollout.

The new administration option for multiple sclerosis treatment could improve access during the COVID-19 pandemic, when availability has been a concern.

Research highlights the need for cardiologists and cardio-oncologists to be involved in the treatment of men with breast cancer due to common risk factors and potential cardiotoxic effects of treatment.

If approved, the biosimilar will be indicated for use in metastatic colorectal cancer, nonsquamous non–small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and metastatic cervical cancer.

Preclinical models have also shown that treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival, according to the study authors.

The FDA has granted Orphan Drug Designation to Uttroside-B (Q Biomed Inc), a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

The FDA has granted the cell-based, off-the-shelf immune primer ilixadencel an orphan drug designation for use as a treatment option in patients with soft tissue sarcoma.

Topics covered in-depth in the show include strategies for patient education, cancer team coordination, side effect monitoring and management of medications from both in-house and external specialty pharmacies.

The FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal melanoma.

NCCN states that all patients with active cancer, or with active, recent, or planned cancer treatment, should be considered highest priority to receive one of the COVID-19 vaccines granted emergency use authorization.

The approval is for a 240 mg injection of nivolumab every 2 weeks or 480 mg every 4 weeks in combination with 40 mg once daily of cabozantinib.